[en] OBJECTIVE: To demonstrate that serum matrix metalloproteinase-3 (MMP-3) is a
variable associated with disease activity and with the response to treatment in
rheumatoid arthritis (RA). METHODS: Serum MMP-3 levels were measured and compared
to biological and clinical disease activity variables in 20 patients with active
RA assessed serially during a one year prospective open label trial with
methotrexate or tenidap. RESULTS: MMP-3 levels were significantly correlated with
C-reactive protein (CRP) and interleukin 6 serum levels as well as with the
disease activity score (DAS), not only at start in untreated patients but also
during the 12 month followup period in both treated groups. Early changes (after
0.5, 1, 2, or 3 months) in MMP-3 levels were significantly associated with change
in DAS observed 4 to 6 months later. CONCLUSION: In addition to CRP, a systemic
marker of inflammation, serum MMP-3 may serve as a consistent synovial derived
marker of RA disease activity, early changes of which predict disease outcome.
Disciplines :
Rheumatology
Author, co-author :
Ribbens, Clio ; Université de Liège - ULiège > Rhumatologie
Badolato R, Oppenheim J. Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum 1996;26:526-38.
Sasaki S, Iwata H, Ishiguro N, Obata K, Miura T. Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 1994;13:228-33.
Yoshihara Y, Obata K, Fujimoto N, Yamashitu K, Hayakawa T, Shimmei M. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 1995;38:969-75.
Manicourt D-H, Fujimoto N, Obata K, Thonar EJ-MA. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Arthritis Rheum 1995;38:1031-9.
Taylor DJ, Cheung NT, Dawes PT. Increased serum proMMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis 1994;53:768-72.
Keyszer G, Lambiri I, Nagel R, et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 1999; 26:251-8.
Cheung NT, Taylor DJ, Evans E, et al. Ytrium-90 synovectomy decreases circulating pro-metalloproteinase-3 in recurrent synovitis [abstract]. Rheumatol in Europe 1996; 25 Suppl:S35.
van Leeuwen MA, van Rijswijk MH, Sluiter WJ, et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997;24:20-7.
Barrera P, Boerbooms AMTh, Janssen EM, et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993;36:1070-9.
Wollheim FA, Ebenhardt KB. The search for laboratory measures of outcome in rheumatoid arthritis. Bailleres Clin Rheumatol 1992;6:69-93.
Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumor necrosis factor-α (cA2) therapy. Br J Rheumatol 1997;36:643-50.
Sipe JD, Bartle LM, Loose LD. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. J Immunol 1992;148:400-4.
Prevoo MLL, van't Hof MA, Kuper UH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
Cheung NT, Mattey DL, Dawes PT, Taylor DJ. Serum pro-matrix metalloproteinase 3 in rheumatoid arthritis: a reflection of local or systemic inflammation? [letter]. Arthritis Rheum 1996;39:884.
Keystone EC, Snow KM, Bombardier C, Chang CH, Nelson DL, Rubin LA. Elevated soluble interleukin-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arthritis Rheum 1988;31:844-9.
Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35:1160-9.
Sharif M, Salisbury C, Taylor DJ, Kirwan JR. Changes in biochemical markers of joint tissue metabolism in a randomized controlled trial of glucocorticoid in early rheumatoid arthritis. Arthritis Rheum 1998;41:1203-9.
Gabay CEM, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
Steiner G, Studnicka-Benke A, Witzmann G, Hofler E, Smolen J. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J Rheumatol 1995;22:406-12.
Seitz M, Loetscher P, Dewald B, et al. Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol 1995;34:602-5.
van Leeuwen MA, Westra J, Limbourg PC, van Riel PLCM, van Rijswik MH. Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study. Ann Rheum Dis 1995;54:674-7.
Arvidson NG, Gudbjornsson B, Elfman L, Ryden AC, Totterman TH, Hallgren R. Cireadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis 1994;53:521-4.
Cholvy H, Combe B, Jaspar J-M, Vrindts Y, Sany J, Malaise M. Stromelysin-1 serum levels in rheumatoid arthritis: association with articular severity [abstract]. Arthritis Rheum 1997;40 Suppl:S150.
Posthumus MD, Westra J, Limburg PC, van Leeuwen MA, van Rijswik MH. Serum levels of matrix metalloproteinase 3 in patients with early rheumatoid arthritis [abstract]. Arthritis Rheum 1998;41 Suppl:S237.
